Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Seoul National University Hospital
Seúl, Corea del SurPublications en collaboration avec des chercheurs de Seoul National University Hospital (14)
2024
-
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Advances in Therapy
-
Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries
Heart and Lung, Vol. 68, pp. 131-144
2023
-
Robotic versus laparoscopic liver resection for huge (â¥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases
HEPATOBILIARY SURGERY AND NUTRITION, Vol. 12, Núm. 2, pp. 205-216
-
Robotic versus laparoscopic liver resection for huge (â¥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases
HEPATOBILIARY SURGERY AND NUTRITION, Vol. 12, Núm. 2, pp. 205-216
2022
-
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
Critical Care, Vol. 26, Núm. 1
-
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease
Nature Reviews Neurology, Vol. 18, Núm. 4, pp. 203-220
2021
-
Pressure injury prediction models for critically-ill patients should consider both the case-mix and local factors
Intensive and Critical Care Nursing
-
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Journal of Clinical Oncology, Vol. 39, Núm. 27, pp. 2991-3001
2020
-
Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study
Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591
2017
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502
2016
-
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550
2015
-
Panobinostat: A novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma
Expert Review of Anticancer Therapy, Vol. 15, Núm. 7, pp. 737-748